Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4 publications
The post-viral GPNMB+ immune niche persists in long-term Covid, asthma, and COPD.
Journal: medRxiv : the preprint server for health sciences
Published: September 10, 2024
A first-in-kind MAPK13 inhibitor corrects stem cell reprogramming and muco-obstructive lung disease.
A first-in-kind MAPK13 inhibitor corrects stem cell reprogramming and muco-obstructive lung disease.
Journal: bioRxiv : the preprint server for biology
Published: September 04, 2024
MAPK13 controls structural remodeling and disease after epithelial injury.
Journal: bioRxiv : the preprint server for biology
Published: June 19, 2024
A correctable immune niche for epithelial stem cell reprogramming and post-viral lung diseases.
Journal: The Journal of clinical investigation
Published: May 16, 2024
Showing 1-4 of 4
Last Updated: 09/26/2026